Wuhan Healthgen Biotechnology Corp. (SHA:688765)
25.67
-1.60 (-5.87%)
At close: Nov 20, 2026
SHA:688765 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 53.03 | 47.21 | 24.06 | 23.47 | 12.82 | 24.84 |
Other Revenue | 0.4 | 0.65 | 1.15 | 0.79 | 0.58 | 0.68 |
| 53.43 | 47.86 | 25.22 | 24.26 | 13.4 | 25.52 | |
Revenue Growth | 88.16% | 89.81% | 3.92% | 81.08% | -47.49% | 18.33% |
Cost of Revenue | 36.59 | 31.53 | 10.68 | 12.2 | 6.18 | 9.9 |
Gross Profit | 16.83 | 16.33 | 14.53 | 12.06 | 7.22 | 15.62 |
Selling, General & Admin | 73.57 | 62.83 | 49.39 | 58.84 | 58.99 | 71.31 |
Research & Development | 89.11 | 92.66 | 116.79 | 159.1 | 110.5 | 75.21 |
Other Operating Expenses | 11.27 | 2.89 | -17.39 | 1.77 | 0.77 | 0.28 |
Operating Expenses | 173.64 | 158.39 | 148.78 | 219.72 | 170.26 | 146.8 |
Operating Income | -156.81 | -142.06 | -134.24 | -207.66 | -163.04 | -131.18 |
Interest Expense | -5.56 | -7.56 | -5.1 | -0.66 | -0.23 | -0.53 |
Interest & Investment Income | 10.23 | 3.01 | 2.4 | 5.79 | 14.64 | 2.73 |
Currency Exchange Gain (Loss) | 0.44 | 0.05 | -0.14 | -0.13 | 0.39 | -0.06 |
Other Non Operating Income (Expenses) | -0.12 | -0.14 | -0.05 | -0.02 | 0 | -0.09 |
EBT Excluding Unusual Items | -151.82 | -146.7 | -137.12 | -202.68 | -148.24 | -129.13 |
Gain (Loss) on Sale of Assets | 2.64 | 3.79 | -1.28 | 1.01 | 0.33 | -11.27 |
Asset Writedown | - | - | - | -0 | - | 0 |
Legal Settlements | -25.61 | -31.24 | -12.97 | - | -1.49 | - |
Other Unusual Items | 36.63 | 17.12 | - | 14.71 | 5.82 | 6.36 |
Pretax Income | -138.17 | -157.04 | -151.37 | -186.96 | -143.58 | -134.04 |
Net Income | -138.17 | -157.04 | -151.37 | -186.96 | -143.58 | -134.04 |
Net Income to Common | -138.17 | -157.04 | -151.37 | -186.96 | -143.58 | -134.04 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 328 | 283 | 268 | 267 | 261 | 216 |
Shares Outstanding (Diluted) | 328 | 283 | 268 | 267 | 261 | 216 |
Shares Change | 22.93% | 5.56% | 0.36% | 2.31% | 20.75% | 333.57% |
EPS (Basic) | -0.42 | -0.56 | -0.56 | -0.70 | -0.55 | -0.62 |
EPS (Diluted) | -0.42 | -0.56 | -0.56 | -0.70 | -0.55 | -0.62 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -770.36 | -666.38 | -220.38 | -224.45 | -424.7 | -263.44 |
Free Cash Flow Per Share | -2.35 | -2.35 | -0.82 | -0.84 | -1.63 | -1.22 |
Gross Margin | 31.50% | 34.12% | 57.64% | 49.71% | 53.89% | 61.21% |
Operating Margin | -293.51% | -296.82% | -532.36% | -855.82% | -1216.74% | -514.08% |
Profit Margin | -258.62% | -328.11% | -600.28% | -770.53% | -1071.49% | -525.26% |
Free Cash Flow Margin | -1441.94% | -1392.31% | -873.96% | -925.01% | -3169.45% | -1032.38% |
EBITDA | -95.36 | -80.19 | -74.7 | -160.56 | -150.66 | -121.52 |
EBITDA Margin | -178.49% | -167.54% | -296.25% | - | - | - |
D&A For EBITDA | 61.45 | 61.88 | 59.54 | 47.1 | 12.38 | 9.67 |
EBIT | -156.81 | -142.06 | -134.24 | -207.66 | -163.04 | -131.18 |
EBIT Margin | -293.51% | -296.82% | - | - | - | - |
Revenue as Reported | 53.43 | 47.86 | 25.22 | - | - | - |
Advertising Expenses | - | 0.57 | 0.3 | 0.12 | 0.07 | 0.13 |